Article
Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.
The Journal of clinical endocrinology and metabolism - 1 Apr 2007
Florez Jose C, Jablonski Kathleen A, Sun Maria W, Bayley Nick, Kahn Steven E, Shamoon Harry, Hamman Richard F, Knowler William C, Nathan David M, Altshuler David
Abstract excerpt
CONTEXT: The common P12A polymorphism in PPARG (a target for thiazolidinedione medications) has been consistently associated with type 2 diabetes. OBJECTIVE: We examined whether PPARG P12A affects progression from impaired glucose tolerance to diabetes, or responses to preventive interventions (lifestyle, metformin, or troglitazone vs. placebo). PATIENTS: This study included 3548 Diabetes Prevention Program...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
